This pre-pivotal trial will begin imminently and is expected to be completed by the end of July. The study will assess the analytical performance of CGM technology enhancements implemented by Trinity Biotech. The data from this analytical performance assessment will be utilised to advance the technical optimization of the next generation CGM device ahead of the pivotal trial that is planned in 2025. Forward-Looking Statements Gary Keating, Ph.D. Eric Ribner (353)-1-2769800 (1)-646-751-4363 E-mail: investorr ...